Enclomiphene citrate is chemically an organic citrate with good photoluminescent properties in organic solutions due to the presence of a tristyrene unit in its structure. Due to the presence of a tertiary amine unit in the structure, it is sensitive to oxidants and is easily oxidized by oxidants to the corresponding nitrogen oxides.
trans-Clomiphene Citrate, stereoisomer of Clomiphene Citrate (C587025), a synthetic estrogen agonist-antagonist. Gonad-stimulating principle.
The effects of the cis and trans isomers of clomiphene citrate on the uterine hexokinase activity of immature ovariectomized rats were studied in long- and short-term experiments. At a dose level of 600 μg/kg, both trans-Clomiphene Citrate and cis-Clomiphene Citrate caused a similar increase in total uterine hexokinase activity observable in 18 hr. When enzyme activity was expressed per g of the uterus (specific activity), significant increases were noted 18 hr after a single injection of trans clomiphene or after 4 daily injections of either isomer. Treatment of these animals with 170-estradiol (5 μg/kg) caused an elevation of both the specific and total hexokinase activities within 18 hr[1].
Enclomiphene citrate (subcutaneous injection, 0.25 and 0.5 mg/animal, daily) inhibits spermatogenesis and decreases serum luteinizing hormone (LH) and testosterone levels in intact or castrated rats[5].
Enclomiphene citrate (oral adminstration, 0.03-3 mg/kg, daily for 90 days) reductes body weight to sham levels, and reduced serum cholesterol[6].
| Animal Model: | 21 days-old Charles River male rats[5] |
| Dosage: | 0.25 and 0.5 mg/animal, daily for 24 days. |
| Administration: | Subcutaneous injection |
| Result: | Decreased LH and testosterone levels in the serum. |
| Animal Model: | OVX (ovariectomy) rat model[6] |
| Dosage: | 0.03, 1, and 3 mg/kg, daily for 90 days. |
| Administration: | Oral adminstration |
| Result: | Reducted body weight to sham levels, and reduced serum cholesterol.
Showed dose-dependent effects on the proximal tibia with BMD and BMC approaching posttreatment Sham levels.
|
[1] D L DiPietro, D A Goss, F J Sanders. “Effect of cis and trans isomers of clomiphene citrate on uterine hexokinase activity.” Endocrinology 84 6 (1969): 1404–8.
![2-{4-[(E)-2-Chloro-1,2-diphenylvinyl]phenoxy}-N,N-diethylethanami ne 2-hydroxy-1,2,3-propanetricarboxylate (1:1) pictures](/ProductImageEN3/2026-08/Small/f55484e3-e53f-42a0-9f41-eb3562292f30.jpg)
